louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00170170: Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
Official title: Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Transplantation
Infection
Cytomegalovirus Infections
Keywords: cytomegalovirus
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2005-09-15
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recipients of liver, kidney, pancreas, heart or lung transplantation

Brief summary: This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.

Detailed description: This study will investigate the clinical and laboratory variables that may be used to predict who among the solid organ transplant recipients will develop CMV disease after completing antiviral prophylaxis. This is a retrospective study of patients seen at the Mayo Clinic during the past five years.

Eligibility criteria: Inclusion Criteria:

* Recipients of liver, kidney, pancreas, heart or lung transplantation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Raymund R. Razonable, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03463070: Misoprostol Before and After Cesarean Section
Official title: The Effect of Misoprostol Given Preoperative Versus Postoperative on Blood Loss With Elective Cesarean Section: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Post Partum Hemorrhage
Keywords: misoprostol
postpartum haemorrhage
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2018-03-13
Enrollment: 140
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: comparison of the effect of misoprostol before and after cesarean on the blood loss

Detailed description: 70 women who received 600 mg misoprostol rectally preoperatively versus 70 women who received 600 mg misoprostol postoperatively at operating theatre

Eligibility criteria: Inclusion Criteria:

* Women not in active labor have reactive non-stress test.
* No contraindications to prostaglandins.
* Have no history of coagulopathy.

Exclusion Criteria:

* Placenta previa.
* Maternal hypertension.
* Diabetes mellitus.
* Previous CS and those with active labor.
* Multiple Fibroid uterus.
* Multiple pregnancies or polyhydramnios.
* Previous myomectomy, previous history of PPH.

Primary outcomes:
measure: intraoperative blood loss
timeFrame: the operation time
measure: postoperative blood loss
timeFrame: every 6 hours during first 24 hours.
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr El Ainiy Hospital
Study officials:
References:
Clinical trial NCT06648070: "Effects of Neuromuscular Reeducation Versus Post Facilitation Stretch Technique for Upper Cross Syndrome Among IT Professionals
Official title: "Effects of Neuromuscular Reeducation Versus Post Facilitation Stretch Technique for Upper Cross Syndrome Among IT Professionals
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Upper Cross Syndrome
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-10-18
Enrollment: 44
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Control Trial
Primary purpose: TREATMENT

Brief summary: This study is a randomised control trial and the purpose of this study is to determine the "Effects of Neuromuscular Reeducation Versus Post Facilitation Stretch Technique for Upper Cross Syndrome among IT professionals .

Detailed description: The purpose of this study is to determine the "Effects of Neuromuscular Reeducation Versus Post Facilitation Stretch Technique for Upper Cross Syndrome among IT professionals

we make 2 groups control and treatment group . we give NMR technique to treatment group and PFS technique to control group in patients with upper cross syndrome.

first we take base line readings of cervical ROM , NPRS AND neck diasbilty index.

after 2 weeks of treatment again we take same readings and compare both readings.

with techniques we also perform strengthning excercise of weal muscles for both groups

Eligibility criteria: Inclusion Criteria:

* IT profressionals
* 20 - 40 years
* Both genders
* Diagnosed UCS
* Pain from 2 months
* Minimum 4 - 6 hiurs working

Exclusion criteria:

* History of cervical spine
* Fracture
* Trauma to neck

Primary outcomes:
measure: Change in ROM
timeFrame: 2 weeks
measure: Pain intensity
timeFrame: 2 weeks
measure: Neck Disability
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT06271070: Analysis of Correlation Between Skin Carotenoid Level and Basic Indicators of Health Status Related to Lifestyle in Vietnamese: An Observational Study
Official title: Analysis of Correlation Between Skin Carotenoid Level and Basic Indicators of Health Status Related to Lifestyle in Vietnamese: An Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lifestyle Risk Reduction
Lead sponsor: KAGOME CO., LTD.
Sponsor class: INDUSTRY
First posted: 2024-02-21
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Visitors to Dr. Binh_TeleClinic

Brief summary: To clarify the relationship between vegetable intake and lifestyle-related disease in Vietnam, we measure skin carotenoid levels and basic indicators of health status related to lifestyle and analyze the correlation between them. This is an important study that can lead to dietary suggestions for preventing lifestyle-related diseases in Vietnam.


Eligibility criteria: Inclusion Criteria:

1. Adults aged 18 years or older
2. Healthy people or patients with metabolic diseases as obesity, diabetes, hypertension, lipid abnormalities, hyperuricemia
3. People who agreed to participate in the study and be able to complete the Informed Consent Form

Exclusion Criteria:

1. Hospitalized patients
2. Patients with other diseases than metabolic diseases as written in inclusion criteria.
3. People judged to be inappropriate by the principal investigator

Primary outcomes:
measure: Skin carotenoid level
timeFrame: single day
measure: Blood markers of lifestyle-related diseases
timeFrame: single day
measure: BMI
timeFrame: single day
measure: Body fat percentage
timeFrame: single day
measure: Blood pressure
timeFrame: single day
Secondary outcomes:
measure: Questionnaire
timeFrame: single day
Other outcomes:
Locations:
city: Hanoi
country: Vietnam
facility: Dr. Binh_Teleclinic - Branch of E2E Solution Company Limited
Study officials:
affiliation: Dr. Binh_Teleclinic - Branch of E2E Solution Company Limited
name: Nguyen Thuy Lan, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Matsumoto M, Suganuma H, Shimizu S, Hayashi H, Sawada K, Tokuda I, Ihara K, Nakaji S. Skin Carotenoid Level as an Alternative Marker of Serum Total Carotenoid Concentration and Vegetable Intake Correlates with Biomarkers of Circulatory Diseases and Metabolic Syndrome. Nutrients. 2020 Jun 19;12(6):1825. doi: 10.3390/nu12061825.
Clinical trial NCT02126670: ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Actinic Keratosis
Lead sponsor: Promius Pharma, LLC
Sponsor class: INDUSTRY
First posted: 2014-04-30
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether or not ACT01 is effective and tolerable alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with facial and/or scalp keratosis.


Eligibility criteria: Inclusion Criteria:

1. Presence of actinic keratosis lesions on the face and/or scalp within a 25 cm2 contiguous area containing at least four lesions that are non-hypertrophic and non-hyperkeratotic and not larger than 6 mm in longest diameter.
2. Age 30-85 years, inclusive.
3. Good general health as determined by investigator and supported by medical history and normal or not clinically significant abnormal vital signs (blood pressure and pulse).

Exclusion Criteria:

1. Severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, pulmonary or renal disease.
2. Dermatologic conditions if present on the face such as acne, atopic dermatitis, seborrheic dermatitis, eczema, rosacea, or albinism.
3. Application of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy to the intended treatment area within 180 days prior to the Baseline Visit.
4. Use of sun lamps or sun tanning beds or booths during the 14 days prior to the Baseline Visit.

Primary outcomes:
measure: Treatment Success at End of Study Visit
timeFrame: up to Day 57
Secondary outcomes:
measure: Irritation Score
timeFrame: up to Day 57
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Therapeutics Clinical Research
state: California
city: Louisville
country: United States
facility: Dermatology Specialists Research, LLC
state: Kentucky
city: High Point
country: United States
facility: Dermatology Consulting Services; Zoe Diana Draelos, MD
state: North Carolina
city: Nashville
country: United States
facility: Tennessee Clinical Research Center
state: Tennessee
Study officials:
References:
Clinical trial NCT02242370: Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
Official title: An Open-label Evaluation of the Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension The MICARDIS COMMUNITY ACCESS TRIAL (MicCAT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-17
Enrollment: 3045
Sex: ALL
Minimum age (years): 20
Maximum age (years): 93
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.


Eligibility criteria: Inclusion Criteria:

* Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg)
* Signed informed consent form

Exclusion Criteria:

- Females of childbearing potential

Primary outcomes:
measure: Change in diastolic blood pressure
timeFrame: Pre-dose, up to 6 weeks after start of treatment
measure: Change in systolic blood pressure
timeFrame: Pre-dose, up to 6 weeks after start of treatment
measure: Changes from baseline in the quality of life (QOL) scores by patient self-assessment
timeFrame: Pre-dose, 6 weeks after start of treatment
Secondary outcomes:
measure: Assessment of blood pressure control rate
timeFrame: Up to 6 weeks after start of treatment
measure: Assessment of systolic blood pressure response rate
timeFrame: Up to 6 weeks after start of treatment
measure: Assessment of diastolic blood pressure response rate
timeFrame: Up to 6 weeks after start of treatment
measure: Change from baseline in pulse pressure
timeFrame: Pre-dose, up to 6 weeks after start of treatment
measure: Number of patients with adverse events
timeFrame: Up to 6 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05372770: Flourish Vaginal Care System to Establish Neovaginal Microbiome
Official title: Pilot Study to Observe Effects of Using Flourish Vaginal Care System to Establish Neovaginal Microbiome After Gender-Confirmation Surgery
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Neovaginal Microbiome
Keywords: neovagina
microbiome
lactobacillus
transgender
probiotic
Lead sponsor: Vaginal Biome Science
Sponsor class: OTHER
Collaborators: name: Papillon Center
First posted: 2022-05-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups of transgender women who have undergone surgery plus a group of healthy cisgender women who have not undergone surgery
Primary purpose: OTHER

Brief summary: This study examines whether use of a commercially-available vaginal wellness system is able to establish a microbiome in transgender women.

Detailed description: Very little is known about the neovaginal microbiome, but it has been described as being a polymicrobial state similar to bacterial vaginosis (BV) in cis women. The Flourish Vaginal Care System is a commercially-available over-the-counter vaginal wellness kit that helps relieve symptoms of BV. This study is intended to determine whether that kit could also help transgender women who have recently undergone gender-confirming surgery to establish a neovaginal microbiome that is dominated by lactobacilli, as observed in healthy cis women. This could increase health and subjective satisfaction of the neovagina. This study examines the (neo)vaginal microbiome in transgender women with and without using Flourish, as well as a group of healthy cisgender women.

Eligibility criteria: Inclusion Criteria:

1. Transgender women over age 18 who are preparing to undergo gender-confirmation surgery.
2. Healthy cisgender women ages 18-52

Exclusion Criteria:

1. Immunosuppressed
2. Known allergies or sensitivities to aloe vera or to other components of Restore®, Balance, or BiopHresh®
3. Known (neo)vaginal infection that is not yeast or BV at start of protocol
4. Inability to tolerate Restore gel by day 13 after surgery.

Primary outcomes:
measure: Vaginal microbiome
timeFrame: Collections at time 0, 6 weeks, and 6 months
measure: Vaginal pH
timeFrame: Collections at time 0, 6 weeks, and 6 months
Secondary outcomes:
measure: VSQ
timeFrame: Collections at time 0, 6 weeks, and 6 months
Other outcomes:
Locations:
city: New Hope
country: United States
facility: Papillon Wellness Center
state: Pennsylvania
Study officials:
affiliation: Papillon Center
name: Christine McGinn, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01260870: European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)
Official title: European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: PAD
Infrapopliteal Lesions
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2010-12-15
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the procedural safety and to identify and characterize therapeutic and functional endpoint assessments in subjects with documented critical limb ischemia who received treatment with the Cotavance Paclitaxel-Coated Balloon vs. those who received POBA only.


Eligibility criteria: Inclusion Criteria:

- Subjects with CLI

Exclusion Criteria:

* Participation in another research trial
* Medical conditions the study doctor will assess

Primary outcomes:
measure: Evaluate procedural safety
timeFrame: 30 days
Secondary outcomes:
measure: Identify and characterize therapeutic and functional endpoint assessments
timeFrame: 5 years
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University
city: Dendermonde
country: Belgium
facility: AZ St.-Blasius Hospital
city: Gent
country: Belgium
facility: University Hospital
city: Bern
country: Switzerland
facility: University Hospital
city: Zurich
country: Switzerland
facility: University Hospital
city: London
country: United Kingdom
facility: St. George's Hospital
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00411970: 20- Versus 23- Gauge System for Pars Plana Vitrectomy
Official title: 20- Versus 23- Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetic Retinopathy
Macular Edema
Postoperative Complications
Vitreous Hemorrhage
Keywords: 23 gauge pars plana vitrectomy
conjunctival erythema and injection
20 gauge pars plana vitrectomy
vitreous and retinal surgery
Lead sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Sponsor class: OTHER
First posted: 2006-12-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to compare the functional and clinical differences and advantages between a standard operating system and a newly developed even smaller system for pars plana vitrectomy.

The present study may work out the possible advantages and disadvantages between the routinely used 20-gauge vitrectomy system and the newly developed 23-gauge device.

Detailed description: 60 patient randomized into 2 groups of 30 each. All of them operated in general anesthesia, vitrectomized and cataract extracted by phacoemulsification if indicated. Preoperative and postoper5ative controls at days 1,2,3 and week 1, month 1,3 and 12 performed. Parameters of interest are: postoperative conjunctival injection, pain, eye pressure, complications intra- and postoperative as well as the durations of surgery divided into opening time, vitrectomy time, retinal manipulation time, closing time.

Eligibility criteria: Inclusion Criteria:

* Over 18 years of age
* Written form of consent
* Vitreous and retinal pathologies requiring surgery

Exclusion Criteria:

* Previous history of vitreous or retinal surgery
* Pregnant or breastfeeding women
* Prohibiting general medical conditions or diseases
* No informed consent signed
* Under 18 years of age

Primary outcomes:
measure: Conjunctival Injection
measure: Subjective postoperative recovery
Secondary outcomes:
measure: Surgery time
measure: Intraocular pressure
measure: Visual acuity
measure: Technically successful surgery (from surgeon's view)
measure: Intra- and postoperative complications
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery
Study officials:
affiliation: Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery
name: Susanne Binder, Prof. MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery
name: Lukas M Kellner, MD
role: STUDY_DIRECTOR
affiliation: Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery
name: Barbara Wimpissinger, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06710470: A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
Official title: Deucravacitinib Pregnancy Study: A Retrospective Observational Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Psoriasis
Keywords: Psoriasis
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2024-11-29
Enrollment: 833
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will include women aged 15 through 50 years with psoriasis who become pregnant (based on their estimated date of conception) from 09-Sep-2022 through 31-Oct-2026 that have been identified in the Optum Research Database (ORD).

Brief summary: This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.


Eligibility criteria: Inclusion Criteria:

* Maternal age 15 through 50 years at date of conception
* Start of pregnancy, defined as the estimated date of conception, during the accrual period (09-Sep-2022 through 31-Oct-2026)
* Continuous medical and pharmacy coverage for a minimum of 6 months prior to and including the estimated date of conception
* Presence of psoriasis from 12 months prior to the date of conception through the end of pregnancy

Exclusion Criteria:

• Exposure to any known teratogens from 5 half-lives prior to the estimated date of conception through the end of the relevant exposure window

Primary outcomes:
measure: Number of infants born with Major Congenital Malformations (MCMs)
timeFrame: Up to 12 months after birth or date of health plan disenrollment
Secondary outcomes:
measure: Pregnancy outcomes
timeFrame: Up to 9 months or date of health plan disenrollment
measure: Infant outcomes
timeFrame: Up to 12 months after birth or date of health plan disenrollment
Other outcomes:
Locations:
city: Lawrenceville
country: United States
facility: Bristol-Meyers Squibb
state: New Jersey
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: